Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

KaloBios Pharmaceuticals, Inc. KBIO

Healthcare Biotechnology
"KaloBios Pharmaceuticals Inc is a biopharmaceutical company. The company focuses on developing medicines for patients with neglected and rare diseases through innovative and responsible business models."


OTCPK:KBIO - Post by User

KaloBios Pharmaceuticals, Inc. > up over $16 to over $43 again
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by RadioDudeon Nov 27, 2015 7:41am
236 Views
Post# 24330633

RE:RE:up over $16 to over $43 again

RE:RE:up over $16 to over $43 againAlso. He was on bloomberg the other day and mentioned how SEC rules prevent him from selling any shares within 6 months of aquiring such a big stake of the float. And that he doesn't plan on selling anyway because he likes KBIO's drugs. 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities